Epidemiology of NAFLD in China Jian-Gao Fan MD, PhD.
|
|
- Clare Thornton
- 5 years ago
- Views:
Transcription
1 Epidemiology of NAFLD in China Jian-Gao Fan MD, PhD. Professor and Director Department of Gastroenterology Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai , China
2 Epidemiological studies in FLD Case definition Liver biopsy CT scan Ultrasound FibroScan/FibroTouch FLI, HSI Sampling frame Population Community Clinical based Hospital based --Consecutive/Non-consecutive
3 Ultrasound of fatty liver
4 Fatty liver in given specific Chinese population Labor workers in Daqing, Liaonin (n=4100): 5% Labor workers in Beijing (n=1050): 11% Employees in Shaoxing, Zhejiang (n=11372): 10% White collars in Beijing (n=818): 18% White collars in Shanghai (n=4009): 13% Among 6553 employees in Lianyungang, Jiangsu: retired cadre 10%, policemen 9%, clerk 6%, workmen 4% Fan JG. Review. Shijie Huaren Xiaohua Zazhi 2001;9:6-10.
5 Increased prevalence of fatty liver in China City Period Subjects Trend *Beijing Administrative officers 23% to 26% Shanghai Factory workers 4% to 14% Wuhan Office workers 12.5% to 24.5% Fan JG, JGH 2007;22: Wang Z. Postgrad Med J 2007;83: * unpublished
6 Increased prevalence of FL in Shanghai factory workers between 1995 and % 50% 40% 30% 20% 10% 0% Fatty liver Habitual drinking FL/Abnormal ALT Obesity Daibetes Hypertension Hyper-TG Hyper-TC Fan JG, et al. J Gastroenterol Hepatol 2007;22:
7 Consensus of management of FLD by Chinese Society of Medicine Guideline for the diagnosis of NAFLD and ALD. Chin J Hepatol 2001 & 2003 Guidelines for diagnosis and treatment of NAFLD & ALD. J Dig Dis 2008; 9: Chinese Guidelines for diagnosis and management of NAFLD & ALD: update J Dig Dis 2011; 12:
8 Definition of NAFLD There is evidence of hepatic steatosis, either by imaging or by histology, and no causes for secondary steatosis. NAFLD is a highly prevalent form of FLD caused by over-nutrition. NAFLD is an acquired metabolic stressinduced liver diseases associated with insulin resistance and genetic susceptibility.
9 Fatty liver in general population in China City/Year Prevalence Etiology Others Shanghai/ % AFL 0.8%, NAFL 15% Other 1.2% Guangzhou/ % AFL 0.5%, NAFL 11.7% Other 1.8% Drinking 13% Children 1.3% Xi an/ % AFL 8.7% (?), NAFL 14.7% Drinking 66% Chengdu/ % AFL 2.6%, NAFL 6.3% Other 3.6% Beijing/ % AFL 4.1%, NAFL 31.3% Shanghai/ /8810 (40-70 yrs in Chongming Island) NAFLD 42.2% 27.6% in NGT, 45.7% in pre-diabetes, 62.5% in diabetes persons Fan, J Hepatol 2005; 43: Zhou, WJG 2007;13: Yan, Hepatol Int 2008; 2:S86-S87. Li, HBPD Int. 2009;8: Yan, JGH; 2013, 28: Yang Z, Sci Rep. 2016;6:37886.
10 Prevalence of Fatty Liver in Shanghai Adults Total 17% Male 19% Female 15% 5% 7% AFL Mixed FL NAFLD 15% AFL 0.8% Mixed FL 1.2% NAFLD 88% Fan JG, et al. J Hepatol 2005; 43:
11 Criteria for obesity and MetS Only 2-3% of Asians classified as obesity by Western criteria. ethnic differences All Asian populations studied had a higher BF% at a lower BMI compared to Caucasians For the same BF%, their BMI was 3-5 units lower compared to Caucasians.
12 Modified definition for Asians Three or more of the following: Central obesity and/or obesity: Waistline >90 cm (M), >80 cm (F) and/or BMI > 25 kg/m 2 Hypertriglyceridaemia: TG 1.7 mmol/l Low HDL-C: <1.03 mmol/l (M), <1.29 mmol/l (F) High blood pressure: 130/85 mmhg. High fasting glucose: FPG 6.1 mmol/l. Fan JG & Pen YD. HBPT Int 2007
13 Fan JG, World J Gastroenterol, 2008; 14:
14 Prevalence of NAFLD/NASH in Shanghai Prevalence of fatty liver and the metabolic syndrome(%) Fatty liver Metabolic syndrome Both prevalence of MetS and NAFLD was 15.3% in Shanghai adults in In NAFLD, prevalence of MetS and abnormal ALT was 52.9% and 12.7%, respectively. Prevalence of NASH might be between 1.9% and 4.1% in Shanghai adults BMI<23 BMI BMI>=25 Fan JG, J Gastroenterol Hepatol 2005 with some data unpublished
15 Prevalence of Lean NAFLD Lean NAFLD is more common in Asia Prevalence of Lean NAFLD in General Population Proportion of Lean NAFLD over all NAFLD USA (Younossi 2012) KOREA (Cho HC 2016) KOREA (Kim HJ 2004) INDIA (Das K 2010) China (Fan 2007)
16 Prevalence of NASH in Shanghai Bao-Steel Company A total of employees of Shanghai Bao-Steel Company were undergone biannual health check-up. Prevalence of abnormal ALT was 4.6%, without obvious changes between 1995 and Prevalence of fatty liver in patients with abnormal ALT was increased between from 25.9% to 51.4%. Prevalence of NAFLD among subjects was 13.1% in 2002, percentage of abnormal ALT among NAFLD patients was 16.4%. Prevalence of NASH might be around 2.2% in health check-up adults in Fan JG, J Gastroenterol Hepatol 2007 with some data unpublished
17 Incidence of NAFLD in Shanghai 5,226 non-drinking workers without US-fatty liver at baseline. After 2-year follow-up, 310 pts (6.2%) were found to have NAFLD. Incidence of NAFLD (3 new cases/100 people/ year) is equal to that in Dionysos study. The baseline BMI, serum triglyceride and their subtle gain during follow-up were independent predictors of incident of NAFLD. Fan JG, et al. Hepatol International, 2010
18 Impact of BMI on incidence and remission of NAFLD < > 30 Incidence of FL Changes of BMI with FL Changes of BMI without FL < > 30 Remission rate of FL Changes of BMI with FL remission Changes of BMI persistent with FL 13.6% (60/440) NAFLD was recovery at the end of 2-year follow-up. Zhou C Fan JG. Chin J Intern Med Chin J Hepatol 2010
19 Increased prevalence of obesity in Asia 8% 7% 6% 5% 4% 3% 2% China Japan Korea India Indonesia 1% 0% Year Fan JG, et al. J Hepatol 2017
20 Global prevalence of NAFLD Younossi Z, et al. Gastroenterology.2016;150:
21 Wang FS, Fan JG, et al. Hepatology 2014; 60:
22 Etiology of fatty liver in liver clinic in Shanghai 6.4% 7.2% 8.3% Non-alcoholic Alcoholic Virus hepatitis Miscellous % 90.00% 80.00% 70.00% 60.00% 50.00% 40.00% 30.00% Percent of abnormal ALT Percent 78.1% 20.00% 10.00% 0.00% NAFLD AFL HBV with FL DILI-FL Percent of NASH might be 20% in out-patients with NAFLD. Fan JG, et al. Shanghai Med J, 1998;21:68-70
23 Liver biopsy from 11 year old male with abnormal LFTs
24 Histological changes in 152 Chinese pts with NAFLD 100% % 60% 40% 20% 0% steatosis(1/2/3) ballonning degeneration (y/n) NAS(1-3;3-4;5) fibrosis(0-4) Male 73.8%, Age :37±10 yrs, BMI: 26±3 kg/m 2 Percent of NASH in biopsy-proven NAFLD was 41.4%. Advanced fibrosis was 15.8%, associated with MetS and severe inflammation. Xun YH, Fan JG, et al. J Dig Dis, 2012; 13:
25 Histological changes of 101 patients with NAFLD Characteristics NAFLD (n=101) None-NASH (n=15) Borderline NASH (n=32) Definitive NASH (n=54) P Steatosis grade,n (%) <0.001 S1 (5-33%) 32 (31.7) 15 (100) 15 (46.9) 2 (3.7) S2 (34-66%) 45 (44.6) 0 17(53.1) 28(51.9) S3 (>66%) 24 (23.8) (44.4) Fibrosis stage, n (%) <0.001 F0 18 (17.8) 7(46.7) 9(28.1) 2(3.7) F1 44 (43.6) 5(33.3) 21(65.6) 18(33.3) F2 26 (25.7) 1(6.7) 1(3.1) 24(44.4) F3 10 (9.9) 2 (13.3) 1(3.1) 7(13.0) F4 3 (3.0) (5.6) Percent of NASH and cirrhosis was 54% and 3%, respectively Both were associated with T2DM and MetS. Shen F, Fan JG. Liver Int 2015; 35:
26 Study profile of NAFLD across the Asia Pacific region the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:
27 Percentage of patients with NASH by country the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:
28 Percentage of patients with advanced fibrosis by country the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:
29 Independent factors discriminating the different histological subgroups the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:
30 Natural history of NAFLD according to data from Asia Annual incidence of NAFLD 3-4% 60% can reverse NAFLD by lifestyle intervention 25% progress from NAFL to NASH and have fibrosis progression in 3 yrs Spontaneous reversal of NASH uncommon without intervention Fibrosis progression 1 stage in 7 yrs in NASH; 1 stage in 14 yrs in NAFL No data on reversal of cirrhosis Normal liver NAFL NASH ± fibrosis Cirrhosis Absence of cirrhosis reported in 30-50% of NAFLD-associated HCC in Asians The absolute risk of HCC in noncirrhotic patients is <0.1% per year HCC 1-4% per year Fan JG, Kim SU, Wong WS. J Hepatol 2017
31 NAFLD leads to liver cancer: do we have sufficient evidence? Duan XY, Qiao L, Fan JG. Cancer letter 2014
32 32
33 80% 70% 60% 50% 40% 30% 20% 10% 0% Obesity Hypertension High TG high TC Diabetes MetS NAFLD n=358 Controls n=788 80% 70% 60% 50% 40% 30% 20% 10% 0% hypertension high TG high TC Diabetes FL with Obesity n=274 FL without Obesity n=84 Obesity alone n=174 Nor FL or obesity n=614 Fan JG, et al. JGH 2007;22:
34 上海宝钢队列糖尿病发病率与危险度比 基线特征 DM 发病数 DM 发病率 (%) 危险度比 (HR) N=12438,follow-up 6 years 95% CI 下限 95% CI 上限 肥胖 BMI <25 kg/m BMI 25 kg/m IFG (-) (+) 高 TG 血症 (-) (+) 高 TC 血症 (-) (+) 脂肪肝 (-) (+) 高 Hb 血症 (-) (+) Fan JG, et al. J Diabetes Investig. 2016; 7:
35 上海崇明脂肪肝流行病学调查 Circulating periostin in relation to insulin resistance and NAFLD among overweight and obese subjects. Sci Rep. 2016;6: Plasma selenium levels and NAFLD in Chinese adults: a cross-sectional analysis. Sci Rep. 2016; 6: Plasma osteoprotegerin levels are inversely associated with NAFLD in patients with type 2 diabetes: A case-control study in China. Metabolism. 2016; 65(4): Association of calf circumference with insulin resistance and NAFLD: the REACTION study. BMC Endocr Disord. 2017;17(1):28. Impaired lung function is associated with NAFLD independently of metabolic syndrome features in middle-aged and elderly Chinese. BMC Endocr Disord. 2017; 17(1):18.
36 Fatty liver & HBV infection in Chinese Inverse association between HBsAg+ve and ultrasound-diagnosed fatty liver both in Shanghai and Taipei. Fan JG, et al. World J Gastroenterol Cheng YL, et al. Plos One 2013 Inverse association between HBV infection and MRS-diagnosed fatty liver in Hong Kong adults. Wong VWS, et al. J Hepatol 2012 Inverse association between HBV infection and hypertriglyceridemia and MetS. Luo et al. Clin Chim Acta. 2007; Jan et al. Int J Obes 2006; Wong et al. J Hepatol 2012
37 Ye DW, Fan JG, et al.aasld,2009
38 Fan JG, et al. AASLD 2016
39 Fatty liver & CHB in Our Group 1 Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol. 2008; 23(5): Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with CHB infection. J Gastroenterol Hepatol. 2008; 23: Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. J Gastroenterol Hepatol. 2012; 27: Hepatic Steatosis Is Highly Prevalent in CHB Patients and Negatively Associated with Virological Factors. Dig Dis Sci. 2014; 59: Saturated fatty acid Inhibits Viral Replication in HBV Infection with NAFLD by TLR4 Mediated Innate Immune Response. Hepat Mon. 2015; 15:e CAP for noninvasive assessment of hepatic steatosis using Fibroscan: Validation in chronic hepatitis B. Dig Dis Sci 2015; 60: Thyroid function is associated with NAFLD in chronic hepatitis B infected subjects. J Gastroenterol Hepatol. 2015; 30: Linked polymorphisms of PNPLA3 confer susceptibility to NASH and decreased viral load in chronic hepatitis B. World J Gastroenterol. 2015; 21: PNPLA3 rs predisposes CHB to hepatic steatosis, but improves insulin resistance and glucose metabolism. J Diabetes Res. 2017; 2017: Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with NAFLD and CHB. Sci Rep. 2017, 7:10517.
40 What are the settings for NAFLD? Overweight/Central obesity 50% Steatosis 10%-40% Steatohepatitis 50% Liver fibrosis 15%~30% Cirrhosis & HCC 30%~40% MetS T2DM Cancer & CVD Liver-related mortality Patrick L. Altern Med Rev, 2002, 7: Fan JG. JGH, 2007;22: JDD 2008;9:63-70
41 NAFLD is not just a Western problem Prevalence of fatty liver increased rapidly in past decades with obesity and MetS pandemic in China. Fatty liver is more often associated with obesity than with alcoholism. Chronic HBV infection do not account for increased trend of fatty liver and fatty liver increased in CHB as well. Cardiovascular and diabetic risk may compete with liver disease-related risk in dictating the final outcome. NAFLD is emerging into a new and major health problem in Chinese. Fan JG. J Hepatol 2009; JGH 2013.
42 Thanks for for your attention!
At Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationLa sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV
WORKSHOP HCV: la guarigione e il parallelismo tra risposta virologica sostenuta e outcome clinico Milano, 25 Ottobre 2018 Ospedale San Raffaele IRCCS - Sede Turro La sindrome metabolica e il suo impatto
More informationAASLD Immune tolerant phase HBV NAFLD diagnostic HCC
AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY
More informationUMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationDownloaded from zjrms.ir at 3: on Monday February 25th 2019 NAFLD BMI. Kg/m2 NAFLD
logistic regression Student s t-test P< BMI BMI P< ALT AST P< Email:mkhoshbaten@yahoo.com Kg/m2 NASH RUQ B C II Case-Control II Logistic Regression Chi-Square T-test P< Grade Model 1- A diffuse hyper echoic
More informationWhat to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationJose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas
Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationThe place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationGuidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010
doi: 10.1111/j.1751-2980.2010.00476.x Consensus report Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010 (Published in Chinese on Chinese Journal of Hepatology
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationAmerican Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationFatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London
Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty liver- how important is it? Importance in terms of: Prevalence Pathogenesis
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationNon-alcoholic fatty liver disease (NAFLD) is a
Original Article / Liver Hepatobiliary & Pancreatic Diseases International The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population Shou-Wu Lee, Teng-Yu Lee,
More informationZhang, Q; Wong, CKH; Kung, K; Chan, JCY; Sy, TWB; Lam, M; Xu, XG; Yang, MF; Yu, Y; Lin, XP; Lam, CLK
Title Development and validation study of a non-alcoholic fatty liver disease risk scoring model among adults in China Author(s) Zhang, Q; Wong, CKH; Kung, K; Chan, JCY; Sy, TWB; Lam, M; Xu, XG; Yang,
More informationNAFLD/NASH in Sub- Saharan Africa
NAFLD/NASH in Sub- Saharan Africa Corné Kruger Gastroenterologist Durbanville Mediclinic Cape Town Liver Interest group meeting: Cape Town 2015 Introduction NAFLD is the most common liver disease disease
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationScreening cardiac patients for advanced liver disease
HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationUnderstanding your FibroScan Results
PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your
More informationNASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014
NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances
More informationParis Hepatology Conference PROGNOSIS OF NASH
Paris Hepatology Conference PROGNOSIS OF NASH Palais des Congrès Monday 15th January 2018 14:45-15:00 PHC 2018 - www.aphc.info Driven to care Disclosures Advisory committees Speaking and teaching Research
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationAssociation between metabolic syndrome and the development of non-alcoholic fatty liver disease
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 77-84, 2013 Association between metabolic syndrome and the development of non-alcoholic fatty liver disease YI WANG 1, YU YUAN LI 2, YU QIANG NIE 2, YONG JIAN ZHOU
More informationWORLDWIDE EPIDEMIOLOGY OF NASH
WORLDWIDE EPIDEMIOLOGY OF NASH Stefano Bellentani, M.D., Ph.D. Chief of Gastroenterology and Hepatology Service Clinica Santa Chiara Locarno Switzerland & Fondazione Italiana Fegato (FIF), Bassovizza (Trieste),
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationNIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01.
NIH Public Access Author Manuscript Published in final edited form as: Am J Med Sci. 2014 January ; 347(1):. doi:10.1097/maj.0b013e31828b25a5. Association Between Metabolic Syndrome and Its Individual
More information6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare
6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,
More information/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT
原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4
More informationInternal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine. ISSN Volume 8 Number 3
Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study Arrigo F. G. Cicero,
More informationDiseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic
Diseases to Watch Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) - Prevalence and Symptoms - Risk Factors and Potential treatments - Target identification for NASH Robert
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationBariatric Surgery and Liver Transplantation
Bariatric Surgery and Liver Transplantation Sammy Saab, MD, MPH, AGAF, FACG, FAASLD Professor of Medicine and Surgery Head, Outcomes Research in Hepatology David Geffen School of Medicine at UCLA Disclosures
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationMetabolic Syndrome and HCC. Jacob George
Metabolic Syndrome and HCC Jacob George MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For
More informationNon alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif
Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationNASH PROGRESS IN THE LAST DECADE
PROGRESS IN THE LAST DECADE Mitchell L. Shiffman, MD, FACG Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need A GLOBAL HEALTH PROBLEM Nigeria Australia Spain
More informationSTOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationBio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis
AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 REVIEW
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationTransient elastography in chronic viral liver diseases
4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION
SL 2-1 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION Mikio KAJIHARA 1,3, Yoshinori HORIE 2,3, Hiromasa ISHII 3 1 Tokyu Hospital, 2 Eiju General
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationNon-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital
WELCOME Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital Presented by DR. PRABIR MOHAN BASAK ASSISTANT PROFESSOR DEPARTMENT
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationAlimentary Pharmacology and Therapeutics SUMMARY. Background Metabolic syndrome is a known risk factor of cirrhosis in chronic hepatitis B (CHB).
Alimentary Pharmacology and Therapeutics Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B a prospective cohort study with paired transient
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationCurrently status of HBV therapy: efficacy and limitations
9 November 2016 Currently status of HBV therapy: efficacy and limitations Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationAssociation of serum adipose triglyceride lipase levels with obesity and diabetes
Association of serum adipose triglyceride lipase levels with obesity and diabetes L. Yang 1 *, S.J. Chen 1 *, G.Y. Yuan 1, L.B. Zhou 2, D. Wang 1, X.Z. Wang 1 and J.J. Chen 1 1 Department of Endocrinology,
More informationNAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
More informationHCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011
HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationPatient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver
Patient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver Derriford Hospital Derriford Road Plymouth PL6 8DH Tel: 01752 431320 www.plymouthhospitals.nhs.uk 1 What is fatty liver?
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationHow to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris
How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris CLINICAL CASE 1996. 54 years old female Department of Primary CV Prevention
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationDiabetes Liver Screen
YOUR LIVER AND YOUR HEALTH Diabetes Liver Screen Non-Alcoholic Fatty Liver Disease (NAFLD) PROF. SUZANNE NORRIS www.liverwellness.ie The spectrum of non-alcoholic fatty liver disease Diabetes Liver Screen
More informationIdentifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional study with pair-matched controls
Shen et al. BMC Gastroenterology (2015) 15:32 DOI 10.1186/s12876-015-0263-9 RESEARCH ARTICLE Open Access Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More information